Italiano, A.

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group

Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 783

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study

Le Cesne, A., Marec-Berard, P., Blay, J.-Y., Gaspar, N., Bertucci, F., Penel, N., Bompas, E., Cousin, S., Toulmonde, M., Bessede, A., et al. (2019) · European Journal of Cancer

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 174

Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158

Marabelle, A., Fakih, M. G., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W., et al. (2019) · Annals of Oncology

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 104

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Peyraud, F., Guégan, J.-P., Bodet, D., Nafia, I., Fontan, L., Auzanneau, C., Cousin, S., Roubaud, G., Cabart, M., Chomy, F., et al. (2022) · Annals of Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 79

LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients

Montero, A. J., Giordano, A., Jhaveri, K., Munster, P., Rodon, J., Lorusso, P., Orr, D., Bartolomé Arcilla, J., Italiano, A., Elias, A., et al. (2024) · Annals of Oncology

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 9